Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease

Molecular Genetics and Metabolism

Volumn 114, Issue 2, 2015, Pages 259-267

  Kizhner, Tali ^a   Azulay, Yaniv ^a   Hainrichson, Mariana ^a   Tekoah, Yoram ^a   Arvatz, Gil ^a   Shulman, Avidor ^a   Ruderfer, Ilya ^a   Aviezer, David ^a,b   Shaaltiel, Yoseph ^a  

^a Protalix Biotherapeutics   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

Enzyme stability; ERT; Fabry disease; Globotriaosylceramide (Gb3); Protein chemical modification; Galactosidase A

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; FUCOSE; GLYCAN DERIVATIVE; HOMODIMER; MANNOSE; PRX 102; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; VEGETABLE PROTEIN; XYLOSE; ISOENZYME; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL COMPOSITION; BOLUS INJECTION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; DRUG STABILITY; DRUG UPTAKE; ENZYME GLYCOSYLATION; ENZYME INACTIVATION; ENZYME REPLACEMENT; ENZYME STABILITY; FABRY DISEASE; FIBROBLAST; HEART; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; KIDNEY PARENCHYMA; LIVER; MALE; MOUSE; NONHUMAN; PLANT CELL CULTURE; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIALYLATION; SINGLE DRUG DOSE; SKIN; SPLEEN; TOBACCO; ANIMAL; CELL CULTURE; ENZYMOLOGY; GENETICS; KIDNEY;

MUS; NICOTIANA TABACUM;

ALPHA-GALACTOSIDASE; ANIMALS; CELLS, CULTURED; ENZYME REPLACEMENT THERAPY; ENZYME STABILITY; FABRY DISEASE; HEART; ISOENZYMES; KIDNEY; LIVER; MALE; MICE; RECOMBINANT PROTEINS; SKIN; SPLEEN; TOBACCO;

EID: 84921653204     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2014.08.002     Document Type: Article

References (44)

1. Parkinson-Lawrence E.J., Shandala T., Prodoehl M., Plew R., Borlace G.N., Brooks D.A. Lysosomal storage disease: revealing lysosomal function and physiology. Physiology 2010, 25:102-115.
2. Anderson W. A case of "Angeio-Keratoma". Br. J. Dermatol. 1898, 10(4):113-117.
3. Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch. Dermatol. Syph. 1898, 43:187-200.
4. Germain D. Fabry disease. Orphanet J. Rare Dis. 2010, 5(1):30.
5. Brady R.O., Tallman J.F., Johnson W.G., Gal A.E., Leahy W.R., Quirk J.M., Dekaban A.S. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease. N. Engl. J. Med. 1973, 289:9-14.
6. Desnick R.J., Dean K.J., Grabowski G., Bishop D.F., Sweeley C.C. Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes. Proc. Natl. Acad. Sci. U. S. A. 1979, 76(10):5326-5330.
7. Lee K., Jin X., Zhang K., Copertino L., Andrews L., Baker-Malcolm J., Geagan L., Qiu H., Seiger K., Barngrover D., et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003, 13:305-313.
8. Sohn Y., Lee J.M., Park H.R., Jung S.C., Park T.H., Oh D.B. Enhanced sialylation and in vivo efficacy of recombinant human alpha-galactosidase through in vitro glycosylation. BMB Rep. 2013, 46:157-162.
9. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. 2001, 345(1):9-16.
10. Brady R.O., Murray G.J., Moore D.F.S., Schiffmann R. Enzyme replacement therapy in Fabry disease. J. Inherit. Metab. Dis. 2001, 24:18-24.
11. Moore D.F., Altarescu G., Herscovitch P., Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol. 2002, 2:4.
12. Moore D.F., Altarescu G., Ling G.S.F., Jeffries N., Frei K.P., Weibel T., Charria-Ortiz G., Ferri R., Arai A.E., Brady R.O., Schiffmann R. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002, 33(2):525-531.
13. Tondel C., Bostad L., Larsen K.K., Hirth A., Vikse B.E., Houge G., Svarstad E. Agalsidase benefits renal histology in young patients with Fabry disease. J. Am. Soc. Nephrol. 2013, 24(1):137-148.
14. Engelen M.A., Brand E., Baumeister T.B., Marquardt T., Duning T., Osada N., Schaefer R.M., Stypmann J. Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Münster Study (FaMüS) data. BMJ Open 2012, 2:e000879. 10.1136/bmjopen-2012-000879.
15. Motwani M., Banypersad S., Woolfson P., Waldek S. Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol. Genet. Metab. 2012, 107(1-2):197-202.
16. Torra R. Renal manifestations in Fabry disease and therapeutic options. Kidney Int. 2008, 74(S111):S29-S32.
17. Aakre K.M., Tondel C., Brun A., Svarstad E. The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. Clin. Nephrol. 2009, 71:118-124.
18. Toyooka K. Fabry disease. Curr. Opin. Neurol. 2011, 24(5):463-468.
19. Gomez M., Molina L., Cladellas M., Ascoeta S., Soler C., Ble M., Ramirez A., Bruguera J. Phenotype and genotype characterization and twin association in patients with Anderson-Fabry cardiomyopathy. Cardiology 2012, 121:71-75.
20. Ramaswami U., Parini R., Pintos-Morell G., Kalkum G., Kampmann C., Beck M. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin. Genet. 2012, 81(5):485-490. on behalf of the, F. O. S. Investigators.
21. Borgwardt L., Feldt-Rasmussen U., Rasmussen A.K., Ballegaard M., Meldgaard Lund A. Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin. Genet. 2013, 83:432-438.
22. Rombach S.M., Smid B., Bouwman M., Linthorst G., Dijkgraaf M.G.W., Hollak C.E.M. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J. Rare Dis. 2013, 8(1):47.
23. Weidemann F., Niemann M., Störk S., Breunig F., Beer M., Sommer C., Herrmann S., Ertl G., Wanner C. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J. Intern. Med. 2013, 274(4):331-341.
24. Mohrenschlager M., Ollert M., Ring J. A study on serum IgE and clinical symptomatology of atopy in patients suffering from the lysosomal storage disorder Fabry disease. J. Eur. Acad. Dermatol. Venereol. 2008, 22:692-695.
25. Rombach S.M., Aerts J.M.F.G., Poorthuis B.J.H.M., Groener J.E.M., Donker-Koopman W., Hendriks E., Mirzaian M., Kuiper S., Wijburg F.A., Hollak C.E.M., Linthorst G.E. Long-term effect of antibodies against infused alpha-galactosidase a in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 2012, 7(10):e47805.
26. Ohashi T., Iizuka S., Ida H., Eto Y. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol. Genet. Metab. 2008, 94:313-318.
27. Pisani A., Porto C., Andria G., Parenti G. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry disease. J. Inherit. Metab. Dis. 2014, 37(1):145-146.
28. Tsukimura T., Kawashima I., Togawa T., Kodama T., Suzuki T., Watanabe T., Chiba Y., Jigami Y., Fukushige T., Kanekura T., Sakuraba H. Efficient uptake of recombinant α-galactosidase a produced with a gene-manipulated yeast by Fabry mice kidneys. Mol. Med. 2012, 18:76-82.
29. Tekoah Y., Ko K., Koprowski H., Harvey D.J., Wormald M.R., Dwek R.A., Rudd P.M. Controlled glycosylation of therapeutic antibodies in plants. Arch. Biochem. Biophys. 2004, 426(2):266-278.
30. Kuster B., Wheeler S.F., Hunter A.P., Dwek R.A., Harvey D.J. Sequencing of N-linked oligosaccharides directly from protein gels: in-gel deglycosylation followed by matrix-assisted laser desorption/ionization mass spectrometry and normal-phase high-performance liquid chromatography. Anal. Biochem. 1997, 250:82-101.
31. Shaaltiel Y., Bartfeld D., Hashmueli S., Baum G., Brill-Almon E., Galili G., Dym O., Boldin-Adamsky S.A., Silman I., Sussman J.L., Futerman A.H., Aviezer D. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol. J. 2007, 5(5):579-590.
32. He X., Haselhorst T., Itzstein M., Kolarich D., Packer N., Kermode A. Influence of an ER-retention signal on the N-glycosylation of recombinant human α-l-iduronidase generated in seeds of Arabidopsis. Plant Mol. Biol. 2012, 79:157-169.
33. Tekoah Y., Tzaban S., Kizhner T., Hainrichson M., Gantman A., Golembo M., Aviezer D., Shaaltiel Y. Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems. Biosci. Rep. 2013, 33(5):771-781. (art:e00071).
34. Lieberman R.L., D'Aquino J.A., Ringe D., Petsko G.A. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry 2009, 48:4816-4827.
35. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., Gass A., Winston J., Dikman S., Fallon J.T., Brodie S., Stacy C.B., Mehta D., Parsons R., Norton K., O'Callaghan M., Desnick R.J. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 2001, 68(3):711-722.
36. Germain D.P., Waldek S., Banikazemi M., Bushinsky D.A., Charrow J., Desnick R.J., Lee P., Loew T., Vedder A.C., Abichandani R., Wilcox W.R., Guffon N. Sustained, long-term renal stabilization after 54months of agalsidase therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 2007, 18:1547-1557.
37. Keslova-Veselikova J., Hulkova H., Dobrovolny R., Asfaw B., Poupetova H., Berna L., Sikora J., Golan L., Ledvinova J., Elleder M. Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients. Virchows Arch. 2008, 45:651-665.
38. Sirrs S. The Fabrazyme shortage - A call to action for metabolic physicians. Mol. Genet. Metab. 2011, 102(1):4-5.
39. Bethencourt V. Virus stalls Genzyme plant. Nat. Biotechnol. 2009, 27:681.
40. Sakuraba H., Murata-Ohsawa M., Kawashima I., Tajima Y., Kotani M., Ohshima T., Chiba Y., Takashiba M., Yoshifumi J., Tomoko F., Tamotsu K., Kohji I. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J. Hum. Genet. 2006, 51:180-188.
41. Bishop D.F., Desnick R.J. Affinity purification of alpha-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms. J. Biol. Chem. 1981, 256(3):1307-1316.
42. Askari H., Kaneski C.R., Semino-Mora C., Desai P., Ang A., Kleiner D.E., Perlee L.T., Quezado M., Spollen L.E., Wustman B.A., Schiffmann R. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch. 2007, 451(4):823-834.
43. Ferraz M.J., Kallemeijn W.W., Mirzaian M., Herrera Moro D., Marques A., Wisse P., Boot R.G., Willems L.I., Overkleeft H.S., Aerts J.M. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2013, 1841(5):811-825.
44. Ioannou Y.A., Zeidner K.M., Gordon R.E., Desnick R.J. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. 2001, 68(1):14-25.